The Medicaid and CHIP Payment and Access Commission (MACPAC) released its June 2026 Report to Congress with recommendations on six policy areas affecting Medicaid managed care operations. The report addresses automation in prior authorization processes, managed care accountability measures, and access to residential treatment services, among other topics. The recommendations also cover community engagement requirements, services for youth with special health care needs, and the Program of All-Inclusive Care for the Elderly (PACE). These recommendations typically inform congressional legislation and CMS policy development over the following 12-24 months.
Why it mattersMACPAC recommendations frequently shape CMS rulemaking and congressional action on managed care oversight, prior authorization requirements, and quality measurement—areas with direct compliance and operational implications for MCOs.
Behavioral Health · LTSS · Managed Care
The National Health Law Program released a report examining how electronic asset verification systems in Medicaid create enrollment barriers for rural residents, particularly Black rural populations. The report identifies gaps in rural banking infrastructure and property transfer documentation that interfere with automated eligibility systems. The analysis focuses on how Medicaid agencies' reliance on electronic verification tools may disproportionately delay or deny coverage for applicants in areas with limited financial institution networks and informal property arrangements. The report provides recommendations for state Medicaid programs to address these verification challenges.
Why it mattersState Medicaid agencies using electronic asset verification may need to modify eligibility procedures to prevent rural enrollment barriers that could affect MCO membership and risk adjustment, particularly in states with rural Medicaid expansion populations.
Managed Care
HHS Secretary Robert F. Kennedy Jr. sent a June 11 letter to the editor-in-chief of Toxicology Reports demanding justification for the removal of a 2021 study linking vaccines to sudden infant death syndrome. Kennedy has cited this research in support of proposed changes to childhood immunization schedules. The retraction raises questions about the scientific basis for potential federal policy shifts affecting Medicaid-covered pediatric vaccine programs. No timeline has been announced for HHS policy changes to childhood vaccination requirements.
Why it mattersMedicaid MCOs cover nearly half of U.S. births and fund childhood vaccines through EPSDT — any federal changes to immunization schedules would require immediate operational, provider education, and quality measure adjustments across pediatric networks.
Maternal · CHIP · Managed Care
Senate Democrats released a policy blueprint proposing measures to lower prescription drug costs ahead of the midterm elections. The proposals aim to address voter concerns about drug affordability and provide a counter-message to White House voluntary pricing initiatives. The blueprint reflects ongoing bipartisan interest in drug pricing reform but does not specify legislative text, implementation timelines, or comment periods. For Medicaid managed care organizations, potential reforms could affect pharmacy benefit management, capitation rate calculations, and prescription drug rebate programs.
Why it mattersDrug pricing legislation could reshape Medicaid pharmacy benefit structures, rebate arrangements, and MCO capitation methodologies if any proposals advance to enacted law.
Pharmacy · Managed Care · Finance
Medicare will begin covering weight loss medications starting next month through a program designed as temporary but expected to face political pressure for permanence. The coverage represents a significant policy shift for Medicare, which has historically excluded anti-obesity drugs from its formulary. The program's implementation comes as GLP-1 medications like Wegovy and Zepbound have demonstrated clinical efficacy for weight management but carry substantial cost implications. While positioned as temporary, the coverage expansion may prove difficult to reverse once beneficiaries begin accessing these medications.
Why it mattersWhile Medicare-specific, this coverage expansion could create precedent and political pressure for similar Medicaid coverage mandates, affecting managed care pharmacy budgets and utilization management strategies for high-cost weight management drugs.
Pharmacy · Managed Care
CMS has issued a proposed rule to codify the Medicare Drug Price Negotiation Program and establish new policies for both the Negotiation Program and the Medicare Prescription Drug Benefit Program as required by the Inflation Reduction Act of 2022. The rule also proposes modifications to the fixed combination drug policy. The Negotiation Program allows Medicare to negotiate prices for certain high-cost drugs, which could affect formulary dynamics and pricing strategies for Medicare Advantage plans that include prescription drug coverage. The proposed rule sets the framework for how negotiated prices will be implemented and administered.
Why it mattersWhile this rule directly affects Medicare Part D plans, dual-eligible beneficiaries enrolled in Medicaid managed care plans may see pharmacy benefit coordination changes, and negotiated drug prices could create pressure for similar Medicaid supplemental rebate strategies.
Pharmacy · Managed Care
The FDA approved Colorado's Section 804 importation program, allowing the state to import certain prescription drugs from Canada to reduce costs for residents. This marks the first operational approval under the 2020 FDA guidance that permits states to seek authorization for Canadian drug importation. The approval comes after years of state planning and federal review. Colorado must now finalize vendor contracts and operational logistics before importing drugs, with implementation timeline still uncertain.
Why it mattersThis precedent-setting approval may prompt other states to pursue importation programs that could affect Medicaid pharmacy benefit design, formulary management, and pharmaceutical cost containment strategies for managed care organizations.
Pharmacy · Managed Care